4 hrs ago
GlaxoSmithKline Rating Reiterated by Bryan Garnier & Cie
's stock had its "neutral" rating restated by equities researchers at Bryan Garnier & Cie in a research report issued on Wednesday, Analyst Ratings.Net reports.
Tue Jun 18, 2013
Glaxo Gets Offer for Thombosis Brands
GlaxoSmithKline has today received an offer for its thrombosis brands and Notre-Dame de Bondeville site from Aspen Global Incorporated and Aspen Pharmacare Holdings Limited.
RDInvesting Provides Investors with Free In-Depth Equity Reports on...
Canadian Solar Inc. shares spiked 7.66 percent to close at $10.12 a share Monday.
Aspen to buy thrombosis drugs from GSK
Aspen Pharmacare said it would acquire the Arixtra and Fraxiparine/Fraxodi brands of thrombosis drug from GlaxoSmithKline, except in China, Pakistan and India.
Mon Jun 17, 2013
GlaxoSmithKline PT Raised to $54.81 at Ubs Ag
UBS AG's price target suggests a potential upside of 4.42% from the stock's previous close.
Glaxo's MS drug under company scrutiny
British pharma GlaxoSmithKline is still looking into "misrepresentations" in data from its research and development labs in China- misrepresentations that led to the halt of an experimental drug for multiple sclerosis.
London Markets: Oil firms boost FTSE 100 after upgrade
Oil firms led U.K. stocks higher after a broker upgrade on Monday, while shares of GlaxoSmithKline PLC also showed upbeat moves after a target price lift.
Sun Jun 16, 2013
The Motley Fool
A Big Pharma Company With a Juicy Dividend Yield and Low Valuation
Anh is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.
Fri Jun 14, 2013
Critical Alerts For Anheuser-Busch InBev, GlaxoSmithKline, Capital...
To see what our analysts have discovered about these stocks read the InvestorsObserver's PriceWatch Alerts at http://www.investorsobserver.com/pr/61320130 Today's PriceWatch Alerts cover the following stocks: Anheuser-Busch InBev , GlaxoSmithKline , Capital One , Safeway , and Onyx Pharmaceuticals .
Diana Furchtgott-Roth: Avandia win a Pyrrhic victory for consumers
After three years of restrictions, advisers to the Food and Drug Administration decided that the diabetes drug rosiglitazone, marketed by GlaxoSmithKline as Avandia, is safe after all, and does not cause undue risk of heart attacks.
Thu Jun 13, 2013
Another GlaxoSmithKline Scandal in China: Bribing Docs to Prescribe Meds?
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! For the second time this month, GlaxoSmithKline is embroiled in scandal in China.
NC Chamber holds manufacturing summit
The North Carolina Chamber is holding its annual summit on manufacturing, where business officials will discuss reform and other issues.
The Winnipeg Free Press
Drug maker GlaxoSmithKline says it investigated China bribery claims, found no wrongdoing
Drug manufacturer GlaxoSmithKline said Thursday it has investigated an accusation that its salespeople in China bribed doctors and found no evidence of wrongdoing.
Wed Jun 12, 2013
TheStreet Reiterates "Buy" Rating for GlaxoSmithKline
's stock had its "buy" rating reaffirmed by TheStreet in a research note issued on Wednesday, Stock Ratings Network reports.
Tue Jun 11, 2013
Glaxo paper 'misrepresented study data'
BRITISH drugmaker GlaxoSmithKline PLC says it dismissed one employee and a second has resigned in the wake of a scandal over misrepresented data in a research paper published in 2010.
GSK offers discount to win UK green light for platelet drug
GlaxoSmithKline has finally won a green light from Britain's healthcare cost agency NICE for its platelet-boosting drug Revolade, after offering a price discount to the country's state-run healthcare service.
The Miami Herald
Glaxo fires worker over misrepresented study data
British drugmaker GlaxoSmithKline PLC says it dismissed one employee and a second has resigned in the wake of a scandal over misrepresented data in a research paper published in 2010.
GlaxoSmithKline Fires Head of Its Chinese R&D Unit for Data Fraud
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! After conducting an internal investigation, GlaxoSmithKline has determined that a scientific paper that was published in Nature Medicine contained fabricated data and has dismissed Jingwu Zang, one of the listed authors, who was a senior vp and head of R&D in ... (more)
GlaxoSmithKline Rating Reiterated by Societe Generale
's stock had its "buy" rating restated by stock analysts at Societe Generale in a report issued on Tuesday, Stock Ratings Network.com reports.
Did You Know the GlaxoSmithKline Us HQ is Really a Sublet 10-By-10 Foot Office?
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Get ready for a trick question.